2,206 reports of this reaction
2.0% of all DABIGATRAN ETEXILATE reports
#9 most reported adverse reaction
DEATH is the #9 most commonly reported adverse reaction for DABIGATRAN ETEXILATE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 2,206 FDA adverse event reports linking DABIGATRAN ETEXILATE to DEATH. This represents approximately 2.0% of all 111,048 adverse event reports for this drug.
Patients taking DABIGATRAN ETEXILATE who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a less commonly reported adverse event for DABIGATRAN ETEXILATE, but still significant enough to appear in the safety profile.
In addition to death, the following adverse reactions have been reported for DABIGATRAN ETEXILATE:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 2,206 FDA reports for DABIGATRAN ETEXILATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 2.0% of all adverse event reports for DABIGATRAN ETEXILATE, making it a notable side effect.
If you experience death while taking DABIGATRAN ETEXILATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.